A5093098626- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Genital Health and Disease
- Advanced Breast Cancer Therapies
- Colorectal and Anal Carcinomas
- Biomarkers in Disease Mechanisms
- Medical Imaging Techniques and Applications
- Urologic and reproductive health conditions
MedSIR (Spain)
2023-2024
Abstract Purpose. The prognostic and predictive role of trophoblast cell-surface antigen-2 (Trop-2) overexpression in human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer is yet unknown. We retrospectively analyzed Trop-2 expression its correlation with clinicopathologic features pathological complete response (pCR) HER2-positive early (EBC) patients treated neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP) the PHERGain study. Methods. at baseline...
Abstract BACKGROUND Combining cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) with first-line ET is the standard of care for pts HR[+]/HER2[-] ABC. PARSIFAL was a randomized, open-label, phase II trial that evaluated efficacy safety first line P plus fulvestrant (F) or letrozole (L) in this population. Both treatments had comparable results (JAMAOncol. 2021;7(12):1791-1799). Although multiple CDK4/6i clinical outcomes biomarkers have been reported, only validated predictive factor...
586 Background: The PHERGain phase II trial (1) (NCT03161353) demonstrated the feasibility of chemotherapy (CT)-free treatment using a PET-based, pCR-adapted strategy in HER2+ EBC pts treated with dual HER2 blockade (trastuzumab pertuzumab; HP). Due to limited PET availability, breast MRI is warranted as an alternative tool for assessing early response. Methods: Briefly, group B were initially HP, and CT was subsequently introduced according on-treatment results. Adjuvant therapy determined...